Virax Biolabs Group Limited (USD) Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits, and med-tech and PPE products for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name; and med-tech and PPE products, such as employee protection equipment products under the ViraxCare brand name, as well as infrared thermometers, pulse oximeters, masks, gloves, and other PPE products. It also distributes nebulizing machines and smart wearable devices that alert employees to help them follow social distance guidelines. In addition, the company operates an online platform that sells ViraxClear and ViraxCare products. It serves clinics, pharmacies, laboratories, hospitals, and other groups, as well as corporations, employees, individual consumers, hospital systems, and public and private institutions. The company operates in Europe, South America, the Asia Pacific, Sub-Saharan Africa, and internationally. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. Virax Biolabs Group Limited was incorporated in 2021 and is headquartered in London, the United Kingdom.

Virax Biolabs Group Limited (USD) Active

30 Broadwick Street, London, GB, W1F 8LX

Stock Price USD

Price Change

Last Dividend USD

B-

Latest Rating

VRAX's stock peer is ALLR (Allarity Therapeutics, Inc.)

VRAX's stock peer is BDRX (Biodexa Pharmaceuticals Plc)

VRAX's stock peer is BWV (Blue Water Vaccines, Inc.)

VRAX's stock peer is CDIO (Cardio Diagnostics Holdings, Inc.)

VRAX's stock peer is HILS (Hillstream BioPharma, Inc.)

VRAX's stock peer is KPRX (Kiora Pharmaceuticals, Inc.)

VRAX's stock peer is KRBP (Kiromic BioPharma, Inc.)

VRAX's stock peer is NRBO (NeuroBo Pharmaceuticals, Inc.)

VRAX's stock peer is PXMD (PaxMedica, Inc. Common Stock)

VRAX's stock peer is QNRX (Quoin Pharmaceuticals, Ltd.)

VRAX's stock peer is REVB (Revelation Biosciences, Inc.)

VRAX's stock peer is UNCY (Unicycive Therapeutics, Inc.)

Healthcare Biotechnology

Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits, and med-tech and PPE products for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name; and med-tech and PPE products, such as employee protection equipment products under the ViraxCare brand name, as well as infrared thermometers, pulse oximeters, masks, gloves, and other PPE products. It also distributes nebulizing machines and smart wearable devices that alert employees to help them follow social distance guidelines. In addition, the company operates an online platform that sells ViraxClear and ViraxCare products. It serves clinics, pharmacies, laboratories, hospitals, and other groups, as well as corporations, employees, individual consumers, hospital systems, and public and private institutions. The company operates in Europe, South America, the Asia Pacific, Sub-Saharan Africa, and internationally. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. Virax Biolabs Group Limited was incorporated in 2021 and is headquartered in London, the United Kingdom.

80%

Dcf Rating

20%

Return On Equity

20%

Return On Assets

60%

Debt To Equity

20%

Price To Earnings

80%

Price To Book

Dividend Stats Yield is calculated via trailing-12-month period

Ex-Dividend	Payment Date	Dividend	Yield	Dividend Frequency
Dividend Data Not Exist

Recent News

Virax Biolabs Enrolls First Patients in Clinical Study Assessing T cell Dysfunction in Post-acute Infection Syndromes

LONDON , March 18, 2025 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, announced today that it has started enrolling patients into its United Kingdom based, multi-center clinical study (NCT06731179). Conducted in collaboration with the United Kingdom's National Health Service, investigators aim to assess the ViraxImmune™ FluoroSpot T cell assay performance in detecting T cell dysfunction in post-acute infection syndrome patients, including those with long COVID, post-treatment Lyme disease (PTLD), and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS).

2025-03-18 07:30:00

Virax Biolabs Presents Data on T-Cell Dysfunction in Post-acute Infection Syndromes at the 19th World Immune Regulation Meeting

LONDON , March 13, 2025 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, today announced it has presented data evaluating the role of T-Cell dysfunction in post-acute infection syndromes (PAIS) at the World Immune Regulation Meeting (WIRM) in Davos, Switzerland. PAISs are often associated with a dysfunction of the immune system, notably progressive T-Cell exhaustion.

2025-03-13 07:30:00

Virax Biolabs to Present at 19th World Immune Regulation Meeting

LONDON , March 5, 2025 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, today announced that the company's management will present at the 19th World Immune Regulation Meeting (WIRM), which will take place March 12-15, 2025, in Davos, Switzerland. Presentation Details: Title: Evaluation of T cell dysfunction in post acute infection syndromes Presenter: Dr. Nigel McCracken, Chief Operating Officer at Virax Biolabs Date: Wednesday, March 12, 2025, at 20:00 Location: Foyer A1, The Congress Center, Davos, Switzerland Additionally, the Company will be showcasing its portfolio of immune profiling products for research use at Booth 116, and management will be available for discussions with research organizations and potential customers.

2025-03-05 07:30:00

Disclaimers

StockQuay.com is not operated by a broker, dealer, or registered investment advisor. Under no circumstances should any information published on StockQuay.com be considered a recommendation to buy, sell, or hold any security. The content on this site and in its associated newsletters is intended solely for informational and educational purposes and does not constitute investment advice or financial recommendations.

Individuals or entities featured or referenced on StockQuay.com may engage in trading activity involving the securities mentioned in any article or report before or after such content is published. These individuals or entities are not affiliated with StockQuay.com, and their inclusion does not imply endorsement or accuracy of their views or actions.

StockQuay.com, its owners, or its affiliates shall not be held liable to any user or third party for any damages or losses arising from the use of content on this website. This includes, but is not limited to, investment losses, loss of profit, loss of data, missed opportunities, or indirect, incidental, or consequential damages.

Data is updated daily and is not guaranteed to be accurate or complete.

Past performance is not indicative of future results. Please conduct your own research or consult with a qualified financial advisor before making any investment decisions